Which diagnostic test should be used to determine whether an Enterobacter cloacae isolate produces a metallo‑β‑lactamase (MBL)?

Diagnostic Testing for MBL-Producing Enterobacter cloacae

For suspected MBL-producing Enterobacter cloacae, use genotypic testing (PCR) as the preferred method, or if unavailable, use the Combined Disc Test (CDT) with a meropenem disc plus EDTA as the most accurate phenotypic alternative.

Testing Algorithm

First-Line Approach: Genotypic Testing

• PCR (Polymerase Chain Reaction) is the gold standard for detecting MBL genes (NDM, VIM, IMP types) 1
• Provides 98-100% sensitivity and specificity when validated against whole genome sequencing 1
• Turnaround time: <3 hours 1
• Directly identifies the specific MBL gene type, which guides treatment decisions

Second-Line Approach: Phenotypic Testing (When PCR Unavailable)

Combined Disc Test (CDT) with EDTA is the recommended phenotypic method 1:

• Technique: Meropenem disc plus EDTA (0.5 M concentration)
• Interpretation: ≥10 mm increase in inhibition zone diameter indicates MBL production 2
• Performance: 100% sensitivity for detecting MBL-producing isolates alone, 96.8% sensitivity when co-producing other carbapenemases 1
• Specificity: 98.8% 1

Alternative phenotypic options (in order of preference):

1. Double-Disk Synergy Test (DDST): Imipenem disc placed 10 mm from EDTA disc - sensitivity 97.9-100%, specificity 87.9-96% 2
2. Modified Carbapenem Inactivation Method with EDTA (eCIM): 95% concordance with PCR 1
3. Moxalactam disc with EDTA: Highly specific for MBL detection, particularly useful for low-level producers 3

Critical Implementation Points

Why This Matters for Patient Outcomes

• Rapid MBL detection is essential because these organisms require fundamentally different treatment than other carbapenem-resistant organisms 1
• MBL-producers are resistant to all β-lactams except aztreonam (when combined with β-lactamase inhibitors) 4
• Mortality rates exceed 50% in some series, making early appropriate therapy critical 5

Common Pitfalls to Avoid

CDT Limitations 1:

• Poor sensitivity (79%) and specificity (55%) for IMP-type MBLs specifically
• Cannot reliably distinguish between different carbapenemase types
• May miss low-level MBL producers if carbapenem MIC is <4 mg/L 2

Automated Systems 1:

• VITEK 2 and Phoenix have lower accuracy for carbapenemase detection
• Should not be relied upon alone for MBL confirmation

Special Considerations for Enterobacter cloacae

Recent epidemiological data shows:

• NDM-1 and VIM-1 are increasingly common in E. cloacae complex, particularly E. hormaechei subspecies 6, 5
• IMP-8 was historically dominant but newer MBL types are emerging 5
• ST171 (NDM-1) and ST78 (VIM-1) clones are spreading in healthcare settings 5

Practical Laboratory Workflow

1. Initial screening: Any Enterobacter cloacae with meropenem MIC ≥1 mg/L or imipenem/ertapenem resistance should trigger carbapenemase testing 1

2. If PCR available: Order bla-NDM, bla-VIM, bla-IMP gene detection 7, 6

3. If PCR unavailable: Perform CDT with meropenem + EDTA disc 1

   • Use 0.5 M EDTA concentration
   • Measure zone diameter difference ≥10 mm as positive
   • Consider confirmatory testing with alternative method if borderline

4. Turnaround time considerations:

   • PCR: 2-3 hours 1
   • CDT: Same-day results (standard disk diffusion timing)
   • This rapid detection enables early appropriate therapy adjustment

The 2023 guidelines explicitly state that genotypic testing should be prioritized where possible, with phenotypic CDT and mCIM/eCIM methods reserved for resource-constrained settings 1. This recommendation is based on the superior accuracy and ability to guide precise antimicrobial selection, which the guideline development group believes will improve clinical outcomes despite lack of direct mortality data 1.